Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) Combined With Nivolumab in Patients With Recurrent High Grade Gliomas
Phase of Trial: Phase I
Latest Information Update: 18 Dec 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Glioma
- Focus Adverse reactions
- 13 Dec 2017 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.
- 13 Dec 2017 Status changed from recruiting to suspended.
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology